AsedaSciences and Hesperos Announce Partnership

AsedaSciences® and Hesperos Announce Strategic Channel Sales Partnership to Accelerate Predictive Safety, Efficacy, and Mechanistic Insights for Drug Discovery

AsedaSciences, a pioneer in machine-learning-guided toxicity risk prediction and cloud-based data visualization, and Hesperos, a leader in Human-on-a-Chip® (HoaC) single- and multi-organ in vitro organ systems, today announced a strategic commercial channel sales and marketing partnership. This alliance integrates the Hesperos HoaC organ system platform that can assess an agent's safety (including on and off-target toxicity), efficacy (via clinically relevant functional readouts) and PK/PD profiles within AsedaSciences advanced data visualization platform, 3RnD®. This partnership unites high-throughput screening methodologies for toxicity and ADME prediction from AsedaSciences and our other partners, with the comprehensive screening models offered by Hesperos. Now, for the first time, data generated by these complimentary methods can be integrated and visualized in a single platform, providing a seamless path to faster, more human-relevant decision-making, accessing a broader potential user base.

"Our partnership with Hesperos represents a major step forward in empowering scientists to make better, earlier decisions with powerful human-relevant data," said Brad Calvin, CEO of AsedaSciences. "Together, we're delivering a unified testing and analytics ecosystem that improves predictiveness across the entire R&D continuum."

The partnership brings together complementary non-animal testing technologies designed to optimize safety, ADME and efficacy predictions to reduce development risk, streamline early R&D, and create a more predictive preclinical workflow.

"AsedaSciences shares our commitment to advancing non-animal testing technologies that better reflect human biology," said Lawrence Florin, CEO of Hesperos, Inc. "Our combined capabilities create a modern, human-relevant alternative to traditional preclinical drug discovery approaches - empowering researchers to cost effectively bring new and better medicines to patients more quickly."

More details coming soon.

About AsedaSciences‍

AsedaSciences provides integrated non-animal screening methods, machine-learning analytics, and cloud-based data visualization for predictive toxicity risk assessment across the chemical-producing industries. Its AI-driven 3RnD® platform enables rapid exploration of structure-activity relationships to support safer compound design early in R&D.

Learn more at http://www.asedasciences.com

About Hesperos

Hesperos is a global contract research organization (CRO) specializing in preclinical drug development services utilizing its Human-on-a-Chip® platform. By replicating key aspects of human biology (and thus avoiding expensive, time-consuming, and often less informative animal testing), Human-on-a-Chip® organ-system models provide product development teams with more meaningful insights that can accurately predict a compound's therapeutic profile while lowering costs and accelerating development timelines.

Learn more at http://www.hesperosinc.com